Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization

Bradney, Curtis P.; Sempowski, Gregory D.; Liao, Hua‐Xin; Haynes, Barton F.; Staats, Herman F.

doi:10.1128/jvi.76.2.517-524.2002

Cited by 85 publications

(73 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, studies have focused on the use of cytokines as intranasal vaccine adjuvants to enhance the immunogenicity of the DNA vaccine because of their potent effects on innate and adaptive immunity as well as functional diversity of immune responses. Studies have shown that cytokines, such as IL-12 [13,14] , IL-2 [15] , IL-15 [16] , type I interferon (IFN) [17,18] , IL-1 [19] , IL-6 [20] , and granulocyte-macrophage colony-stimulating factor (GM-CSF) [21] , enhanced antigen-specific immunity following delivery with different antigens.…”

Section: Introductionmentioning

confidence: 99%

Intranasal co-delivery of IL-6 gene enhances the immunogenicity of anti-caries DNA vaccine

et al. 2014

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: To investigate the effects of co-delivering IL-6 expressing plasmid pCI-IL-6 on the immunogenicity of the anti-caries DNA vaccine pCIA-P, which encodes the surface protein antigen PAc of Streptococcus mutans. Methods: Plasmid pCI-IL-6 was constructed by inserting the murine IL-6 gene into the pCI vector. Expression of IL-6 in vitro was assessed using Western blot analysis. BALB/c mice were intranasally co-immunized with pCIA-P plus pCI-IL-6 on d 0 and 14. Anti-PAc IgG and secretory IgA (sIgA) were assessed by ELISA. Splenocytes from the mice were re-stimulated with the PAc protein, and IFN-γ and IL-4 production was measured using ELISA. Splenocyte proliferation was analyzed with flow cytometry. Rats were similarly immunized, and dental caries scores were determined using the Keyes method. Results: Marked expression of IL-6 was found in COS-7 cells transfected with pCI-IL-6. In the pCI-IL-6 co-immunized mice, the specific IgG antibodies in serum and sIgA antibodies in saliva were significantly higher than those in the control mice at weeks 4 and 8. Moreover, the secretion of IFN-γ from splenocytes in response to re-stimulation with PAc protein was significantly higher in the pCI-IL-6 co-immunized mice than that in the control mice, whereas the secretion of IL-4 had no significant difference. The proliferation of splenocytes from the pCI-IL-6 co-immunized mice was significantly higher than that from the mice immunized with pCIA-P and pCI vector. In the rat caries model, the pCI-IL-6 co-immunization rats displayed lower caries scores than the control rats. Conclusion: Intranasal co-delivery of IL-6 gene significantly enhances the immunogenicity of the anti-caries DNA vaccine.

show abstract

Section: Introductionmentioning

confidence: 99%

Intranasal co-delivery of IL-6 gene enhances the immunogenicity of anti-caries DNA vaccine

et al. 2014

Acta Pharmacol Sin

View full text Add to dashboard Cite

show abstract

“…Others have used IL-12 as a mucosal adjuvant for intrarectal immunization against HIV-1 peptides and were able to generate systemic and local cytotoxic responses, but those investigators did not examine induction of protective mucosal antibodies (6). Recently, Bradney et al (9) used IL-12 coadministered with proinflammatory cytokines as adjuvants for anti-HIV i.n. immunization.…”

Section: Vol 77 2003 Induction Of Mucosal Immunity To Hiv-1 5593mentioning

confidence: 99%

“…In particular, it has been shown that interleukin-12 (IL-12) and cholera toxin subunit B (CTB) are highly effective vaccine adjuvants that can be delivered to mucosal sites to modulate both mucosal and systemic immunity to viral vaccines (3,6,9,22).…”

mentioning

confidence: 99%

Intranasal Vaccination Using Interleukin-12 and Cholera Toxin Subunit B as Adjuvants To Enhance Mucosal and Systemic Immunity to Human Immunodeficiency Virus Type 1 Glycoproteins

Albu

Jones-Trower

Woron

et al. 2003

J Virol

View full text Add to dashboard Cite

We have investigated the induction of protective mucosal immunity to human immunodeficiency virus type 1 (HIV-1) isolate 89.6 by intranasal (i.n.) immunization of mice with gp120 and gp140 together with interleukin-12 (IL-12) and cholera toxin subunit B (CTB) as adjuvants. It was found that both IL-12 and CTB were required to elicit mucosal antibody responses and that i.n. immunization resulted in increased total, immunoglobulin G1 (IgG1), and IgG2a anti-HIV-1 antibody levels in serum; increased total, IgG1, IgG2a, and IgA antibody expression in bronchoalveolar lavage fluids; and increased IgA antibody levels in vaginal washes. Levels of anti-HIV-1 antibodies in both sera and secretions were higher in groups immunized with gp140 than in those immunized with gp120. However, only gp120-specific mucosal antibodies demonstrated neutralizing activity against HIV-1 89.6. Taken together, the results show that IL-12 and CTB act synergistically to enhance both systemic and local mucosal antibody responses to HIV-1 glycoproteins and that even though gp140 induces higher antibody titers than gp120, only gp120-specific mucosal antibodies interfere with virus infectivity.

show abstract

“…This debate has converged on the consensus that both arms of the immune response will likely be necessary to achieve effective HIV-1 vaccination (1, 2). Additionally, the field has turned toward investigating TLR agonists and other adjuvants to enhance dendritic cell antigen presentation and augment vaccine-elicited responses (3)(4)(5)(6)(7)(8). Despite repeated attempts to produce an efficacious HIV-1 vaccine, our knowledge of the adjuvant-specific impact on both the humoral and cellular arms of vaccine-elicited immune responses is still nascent.…”

mentioning

confidence: 99%

Which comes first: the antigen or the adjuvant?

Permar¹,

Staats²

2014

J. Clin. Invest.

Self Cite

View full text Add to dashboard Cite

Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization

Cited by 85 publications

References 52 publications

Intranasal co-delivery of IL-6 gene enhances the immunogenicity of anti-caries DNA vaccine

Intranasal co-delivery of IL-6 gene enhances the immunogenicity of anti-caries DNA vaccine

Intranasal Vaccination Using Interleukin-12 and Cholera Toxin Subunit B as Adjuvants To Enhance Mucosal and Systemic Immunity to Human Immunodeficiency Virus Type 1 Glycoproteins

Which comes first: the antigen or the adjuvant?

Contact Info

Product

Resources

About